Ace Vision Group Names Ken Araki to Its Board of Directors
Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named Ken Araki to its board of directors. Mr. Araki brings executive management experience and strategic leadership skills to support and drive commercial planning for the VisioLite® laser. The laser restores the eye’s natural dynamic range of focus through Laser Scleral Microporation (LSM), allowing patients to see clearly at all distances with the eye’s natural functionality. The VisioLite® Ophthalmic Laser System & LSM are not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.
Explore More Articles
Jackson discusses laser scleral microporation for presbyopia
LAS VEGAS — In this Healio Video Perspective from the ASCRS meeting, Mitchell A. Jackson, MD, discusses preliminary results from a trial investigating laser scleral microporation to treat presbyopia.
read moreLaser scleral microporation may solve biomechanical problem of presbyopia
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Alex Lopez of Ace Vision Group discusses laser scleral microporation for presbyopia. Lopez said the GenII device can potentially deliver improved near vision without compromising distance vision in patients with presbyopia. The company plans to do a study in the United States in 2026, potentially leading to commercial availability in …
read moreOcular Health Implications of the Loss of Dynamic Range of Focus Function in Presbyopia
Presbyopia is defined as the eye’s loss of ability to focus on objects at near distances, and it is the most common cause of age-related vision impairment. Presbyopia is a significant global health issue that is underdiagnosed. It affects all people in their 40s and older: an estimated 90 million people in the United States …
read more